L
@houndcl
Followers
3K
Following
14K
Media
1K
Statuses
8K
Making every data point count. Schrödinger's chemist. Imperfection makes a drug. Husband & Dad. All opinions ∈ {me}.
Joined January 2012
$BHVN Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder. #FAIL …and good news for $AXSM $JNJ / $ITCI
2
0
8
$CYTK no new news is good news type post Mid-Cycle Mtg - ...typically a lot of general details in the REMS should already be on the table for the midcycle mtg - .. jmho.
1
0
10
Gonna vote $REPL. Might waste a slot eventually. It could be the most interesting PDUFA in 2026. Survive or break.
2
0
15
How many patients received second-line advanced KRas inhibitor tx after progression on mGnP + Atebimetinib? Is the single-arm OS artificially inflated by this factor?
$IMRX Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 • BioPharmCatalyst
2
0
9
Anyone has access to https://t.co/dAnCdUm2n1? It asks for username and password.
3
0
3
Early decision is usually good news. but in this case, label is more important. don't fk up. otherwise, you will be flooded with meme.
0
0
16
Got many insightful comments. Thx all. Want to be crystal clear: this is good data! LLY Orfo set a high bar. Also an implication to the new players: the weight loss target matters. Literally you can't use a med which is only able to reach -15% at terminal to maintain a -25% wl.
1
0
2
This essentially puts "I can use low dose x / more tolerable regimen y to maintain the deep weight loss achieved by z induction" thesis at risk.
3
0
5
This result makes me worry about all weight loss maintenance plays. A clear weight rebound from GLP1/GIP dual agonist to GLP1 agonist. The terminal efficacy which is a function of MoA & dose is in action. Weight control is like a spring, you push less harder, it bounces back.
11
2
30
Look like they decided to deprioritize Temu calendar
@DickMedChem Their calendar is from teemu
1
0
6
As predicted "Accordingly, the Company does not intend to advance OV350 IV further in the clinic."
Level set the expectation on OV350 p1 readout in Q4. It is clear to me $OVID wants to discontinue OV350 then focus on the next gen oral KCC2 activator, OV4071. This readout should be viewed as FIH MoA derisking event. As long as there is no clear on-target tox, so be it.
4
0
25
Everything makes sense now. - Friday call buyer knew 22 abstracts are coming - Marc called Lilly to fetch their 5 abstracts in person. - The other 17 abstracts are being discussed in the Intralink - JPM Marc will have 1:1 with other leaders for Q&A "We had lots of inbounds."
1
0
15
abvx needs to set 3 intralinks in parallel to let the other side fully digest 22 abstracts before maintenance data hit in Q2 2026.
2
0
33